๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Methotrexate, paclitaxel, ifosfamide, and cisplatin in poor-risk nonseminomatous germ cell tumors

โœ Scribed by Dimitrios Pectasides; Eirini Pectasides; George Papaxoinis; Nikolaos Xiros; Konstantinos Kamposioras; Nikolaos Tountas; Theofanis Economopoulos

Book ID
116956427
Publisher
Elsevier Science
Year
2010
Tongue
English
Weight
233 KB
Volume
28
Category
Article
ISSN
1078-1439

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Cisplatin-based (PVB+M) chemotherapy in
Cisplatin-based (PVB+M) chemotherapy in good-risk and poor-risk nonseminomatous germ cell tumors
โœ Dr. Tapan Saikia; Upendra Hegde; Suresh Advani; Gopal Ramakrishnan; Jagdeesh Kul ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 313 KB

Twenty-seven patients with metastatic nonseminomatous germ cell tumors were treated with Cisplatin, vinblastine, bleomycin, and low-dose methotrexate (PVB + M) combinations. Patients were divided into good-risk and poor-risk groups. All seven patients (100%) with good-risk factors achieved complete

Paclitaxel + BEP (T-BEP) Regimen as Indu
Paclitaxel + BEP (T-BEP) Regimen as Induction Chemotherapy in Poor Prognosis Patients With Nonseminomatous Germ Cell Tumors: A Phase II Study
โœ A. Tryakin; M. Fedyanin; D. Kanagavel; I. Fainstein; J. Sergeev; B. Polockij; V. ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 305 KB

## Objectives: To evaluate paclitaxel, bleomycin, etoposide, and cisplatin (t-bep) in patients with poor-prognosis nonseminomatous germ cell tumor (nsgct). paclitaxel is an active treatment of nonseminomatous germ cell tumors. ## Methods: The present study was an open-label, single-center, phase